INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation Pharmaceutical Investing
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options Biotech Investing
Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group for TRULANCE (plecanatide) in China Life Science Investing
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement Pharmaceutical Investing
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse for Treatment of Pulmonary Arterial Hypertension Pharmaceutical Investing
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights Pharmaceutical Investing
